Literature DB >> 21680704

Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.

Yiwei Li1, Dejuan Kong, Zhiwei Wang, Aamir Ahmad, Bin Bao, Subhash Padhye, Fazlul H Sarkar.   

Abstract

The development of prostate cancer and its progression to castrate-resistant prostate cancer (CRPC) after antiandrogen ablation therapy are driven by persistent biological activity of androgen receptor (AR) signaling. Moreover, studies have shown that more than 50% of human prostate cancers overexpress ERG (v-ets avian erythroblastosis virus E26 oncogene related gene) due to AR-regulated TMPRSS2-ERG fusion gene. However, the reported roles of TMPRSS2-ERG fusion in cancer progression are not clear. In this study, we investigated the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network for studying the aggressive behavior of prostate cancer cells and further assessed the effects of BR-DIM and CDF [natural agents-derived synthetic formulation and analogue of 3,3'-diindolylmethane (DIM) and curcumin, respectively, with improved bioavailability] on the regulation of AR/TMPRSS2-ERG/Wnt signaling. We found that activation of AR resulted in the induction of ERG expression through TMPRSS2-ERG fusion. Moreover, we found that ERG overexpression and nuclear translocation activated the activity of Wnt signaling. Furthermore, forced overexpression of ERG promoted invasive capacity of prostate cancer cells. More important, we found that BR-DIM and CDF inhibited the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network, leading to the inactivation of Wnt signaling consistent with inhibition of prostate cancer cell invasion. In addition, BR-DIM and CDF inhibited proliferation of prostate cancer cells and induced apoptotic cell death. On the basis of our findings, we conclude that because BR-DIM and CDF downregulate multiple signaling pathways including AR/TMPRSS2-ERG/Wnt signaling, these agents could be useful for designing novel strategies for the prevention and/or treatment of prostate cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680704      PMCID: PMC3167947          DOI: 10.1158/1940-6207.CAPR-11-0077

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  48 in total

1.  Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.

Authors:  Vanessa C Thompson; Antonio Hurtado-Coll; Dmitry Turbin; Ladan Fazli; Melanie L Lehman; Martin E Gleave; Colleen C Nelson
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  c-Myc stimulates cell invasion by inhibiting FBX8 function.

Authors:  Hyun Jung Cho; Yun Jeong Oh; Junhye Kwon; Jae Young Kwon; Kyung-Soo Kim; Hongtae Kim
Journal:  Mol Cells       Date:  2010-09-10       Impact factor: 5.034

4.  Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.

Authors:  D Hawksworth; L Ravindranath; Y Chen; B Furusato; I A Sesterhenn; D G McLeod; S Srivastava; G Petrovics
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-09-07       Impact factor: 5.554

5.  Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.

Authors:  Nuria Coll Bastus; Lara K Boyd; Xueying Mao; Elzbieta Stankiewicz; Sakunthala C Kudahetti; R Tim D Oliver; Daniel M Berney; Yong-Jie Lu
Journal:  Cancer Res       Date:  2010-10-14       Impact factor: 12.701

6.  FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.

Authors:  Santosh Gupta; Kristiina Iljin; Henri Sara; John Patrick Mpindi; Tuomas Mirtti; Paula Vainio; Juha Rantala; Kalle Alanen; Matthias Nees; Olli Kallioniemi
Journal:  Cancer Res       Date:  2010-08-16       Impact factor: 12.701

7.  Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Authors:  Karin G Hermans; Joost L Boormans; Delila Gasi; Geert J H L van Leenders; Guido Jenster; Paul C M S Verhagen; Jan Trapman
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

8.  Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

Authors:  Kati K Waltering; Merja A Helenius; Biswajyoti Sahu; Visa Manni; Marika J Linja; Olli A Jänne; Tapio Visakorpi
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

9.  Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.

Authors:  X Yu; Y Wang; D J DeGraff; M L Wills; R J Matusik
Journal:  Oncogene       Date:  2010-12-13       Impact factor: 9.867

10.  Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Authors:  Michael C Haffner; Martin J Aryee; Antoun Toubaji; David M Esopi; Roula Albadine; Bora Gurel; William B Isaacs; G Steven Bova; Wennuan Liu; Jianfeng Xu; Alan K Meeker; George Netto; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

View more
  24 in total

1.  Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog.

Authors:  Aamir Ahmad; Afreen Sayed; Kevin R Ginnebaugh; Vivek Sharma; Anita Suri; Arundhati Saraph; Subhash Padhye; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism.

Authors:  Asfar S Azmi; Shadan Ali; Sanjeev Banerjee; Bin Bao; Mai N Maitah; Subhash Padhye; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2011-07-26       Impact factor: 4.060

Review 3.  Wnt and SHH in prostate cancer: trouble mongers occupy the TRAIL towards apoptosis.

Authors:  A A Farooqi; S Mukhtar; A M Riaz; S Waseem; S Minhaj; B A Dilawar; B A Malik; A Nawaz; S Bhatti
Journal:  Cell Prolif       Date:  2011-10-04       Impact factor: 6.831

4.  Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.

Authors:  A A Goldberg; V I Titorenko; A Beach; K Abdelbaqi; S Safe; J T Sanderson
Journal:  Invest New Drugs       Date:  2013-05-25       Impact factor: 3.850

Review 5.  Antioxidant function of isoflavone and 3,3'-diindolylmethane: are they important for cancer prevention and therapy?

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Fazlul H Sarkar
Journal:  Antioxid Redox Signal       Date:  2013-03-14       Impact factor: 8.401

Review 6.  Perspectives on new synthetic curcumin analogs and their potential anticancer properties.

Authors:  Alok Vyas; Prasad Dandawate; Subhash Padhye; Aamir Ahmad; Fazlul Sarkar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Advances in androgen receptor targeted therapy for prostate cancer.

Authors:  Alia Ahmed; Shadan Ali; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

8.  Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Authors:  Katri A Leinonen; Outi R Saramäki; Bungo Furusato; Takahiro Kimura; Hiroyuki Takahashi; Shin Egawa; Hiroyoshi Suzuki; Kerri Keiger; Sung Ho Hahm; William B Isaacs; Teemu T Tolonen; Ulf-Håkan Stenman; Teuvo L J Tammela; Matti Nykter; G Steven Bova; Tapio Visakorpi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-01       Impact factor: 4.254

9.  The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.

Authors:  Kuo-Cheng Huang; Mohammed Alshalalfa; Samar A Hegazy; Michael Dolph; Bryan Donnelly; Tarek A Bismar
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

10.  Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA.

Authors:  Shaan Sarkar; Hala Dubaybo; Shadan Ali; Priscila Goncalves; Sri Lakshmi Kollepara; Seema Sethi; Philip A Philip; Yiwei Li
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.